Moderna begins first US pivotal Covid-19 vaccine study, lands $472M more from BARDA
After weeks of buildup and controversial delays, Moderna has launched its pivotal study to determine whether their Covid-19 vaccine actually works. And BARDA is committing another $472 million to get them there.
The 30,000 person study will test whether two 100 µg doses of their mRNA vaccine can prevent people from becoming symptomatic with Covid-19. The launch marks the beginning of a second stage in the hunt for a coronavirus vaccine, as the most well-backed and advanced efforts — having been tested for safety and immunogenicity in small groups of volunteers — move into studies that will determine whether they can actually prevent Covid-19 and be available in the fall or winter to stem the pandemic.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.